ARTICLE | Clinical News
Batimastat BiodivYsio stent: BII and BBG started BRILLIANT II, a double-blind, 400-patient pivotal European trial of the Batimastat BiodivYsio stent. The study
January 7, 2002 8:00 AM UTC
Biocompatibles International plc (LSE:BII), Farnham, U.K. British Biotech plc (LSE:BBG; BBIOY), Oxford, U.K. Product: Batimastat BiodivYsio stent Business: Cardiovascular Therapeutic category: Throm...